Massimo Cristofanilli, MD, FACP
Professor of Medicine
Robert Lurie Cancer Center, Northwestern University
Dr. Cristofanilli reciveived his medical degree in 1986 from the University “La Sapienza” Medical School in Rome (Italy) where he subsequently completed a Fellowship in Medical Oncology in November 1990. In July 1996, he started a Medical Oncology Fellowship at the University of Texas M. D. Anderson Cancer Center. Between 1998 and 2010 he held a faculty position in the Department of Breast Medical Oncology at the University of Texas M. D. Anderson Cancer Center where serving as an Associate Professor of Medicine and Executive Director of the Morgan Welch IBC clinic and research program that he founded in 2006. In 2010 he joined the Fox Chase Cancer Center in Philadelphia as Chairman of Medical Oncology, Leader of the Breast Service Line and co-Leader of the Women Cancer Program. Subsequently, he served as Director of the Jefferson Breast Cancer Center and Clinical program and Deputy Director of Translational Research at the SKCC. He is currently the Associate Director of Translational Research and Precision Medicine at the Robert Lurie Comprehensive Cancer Center and Director of the oncoSET Program.
His major research interest consists in the detection, characterization and possible therapeutic targeting of occult (microscopic) disease in breast cancer. His initial work using a novel immunomagnetic-based technology (CellSearch™) led to a pivotal trial which successfully demonstrated the detection and prognostic value of circulating tumor cells (CTCs) in the peripheral blood of patients with metastatic breast cancer (MBC). Several seminal papers resulted from this initial study that have also fostered research in other tumor types and expanded the potential implication of microscopic disease in advanced cancer. My interest in molecular diagnostics has recently expanded to define the role, applications and clinical implications of tissue-based (NGS, RPMA) and blood-based testing (ctDNA). He has been involved in the development of new targeted agents in metastatic disease (e.g. lapatinib and gefitinib). In particular, he lead an investigator-initiated multicenter trial that successful demonstrated the superiority of combining an EGFR-inhibitor (Gefitinib) with anastrozole in postmenopausal women with hormone-receptor positive disease starting hormonal therapy. More recently, he was the lead investigator for the prospective, multicenter clinical trial evaluating palbociclib (IBRANCE) in combination with fulvestrant (Faslodex) in patients with hormone-receptor positive MBC-PALOMA- 3.
Most relevant publications:
1. Cristofanilli M, De Gasperis G, Zhang L, Hung MC, Gascoyne PR, Hortobagyi GN. Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. Clin Cancer Res 8:615-9, 2002.
2. Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C., Reuben, J.M., Doyle, G.V., Allard, W.J., Terstappen, L.W., Hayes, D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351:781-91, 2004.
3. Budd, T.G., Cristofanilli, M., Ellis, M.J., Stopeck, A., Borden, E., Miller, C.M., Matera, J., Repollet, M., Doyle, G.V., Terstappen, L.W., Hayes, D.F. Circulating tumor cells versus imaging: Predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12:6403-6409, 2006.
4. Hayes, D.F., Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Miller, M.C., Matera, J., Allard, W.J., Doyle, G.V., Terstappen, L.W. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12:4218-4224, 2006.
5. Cristofanilli M, Valero V, Buzdar U, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. Cancer 110(7):1436-1444,
6. Robertson FM, Woodward WA, Pickei R, Ye Z, Bornmann W, Pal A, Peng Z, Hall CS, Cristofanilli M. Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. Cancer 116(11 Suppl):2760-2767, 2010. PMID:20503408/NIHMS189768
7. Boussen, H., Cristofanilli, M., Zaks, T., DeSilvio, M., Salazar, V., Spector, N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib in combination with paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 28:3248-3255, 2010. PMC Journal
8. Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S, Cristofanilli M. Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat. 2013 Jul;140(1):23-33. doi: 10.1007/s10549-013- 2600-4.
9. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: Safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 107(5):935-44, 2006.
10. Cristofanilli, M., Valero, V., Mangalik, A., Royce, M., Rabinowitz, I., Arena, F.P., Kroener, J.F., Curcio, E., Watkins, C., Bacus, S., Cora, E.M., Anderson, E., Magill, P. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin. Cancer Res. 16:1904-1914, 2010. doi: 10.1158/1078-0432.CCR-09- 2282.
11. Turner NC, Jungsil R, Andre F., Loi S., Verma S., Hiroji I., Harbeck N., Loibi S., Bartlett CH., Ke Z., Giorgetti C., Randolph S., KoehlerM., Cristofanilli M. Palbociclib in Hormone-Receptor- Positive Advanced Breast Cancer. N Engl J Med 2015; 373:209-219.doi: 10.1056/NEJMoa1505270.
12. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016. pii: S1470-2045(15)00613- 0. doi: 10.1016/S1470-2045(15)00613- 0.
13. Van Laere SJ, Ueno NT, Finetti P, Vermeulen PB, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam PA, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix LY, Reuben JM, Bertucci F. Uncovering the molecular secrets of Inflammatory Breast Cancer biology: An integrated analysis of three distinct Affymetrix gene expression data sets. Clin Cancer Res. 2013 Feb 8
14. Jeselsohn R; Yelensky R., Guchwalter G., Frampton G.M., Meric-Bernstam F., Gonzalez-Angulo A.M., Ferrer-Lozano J., Perez-Fidalgo A., Cristofanilli M., et al. Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor positive breast cancer. Clinical Cancer Research 2014 ;20(7):1757-67. doi: 10.1158/1078-0432.CCR- 13-2332.
15. Zhang EY, Cristofanilli M, Robertson F, Reuben JM, Mu Z, Beavis RC, Im H, Snyder M, Hofree M, Ideker T, Omenn GS, Fanayan S, Jeong SK, Paik YK, Zhang AF, Wu SL, Hancock WS. Genome Wide Proteomics of ERBB2 and EGFR and Other Oncogenic Pathways in Inflammatory Breast Cancer. J Proteome Res. 2013 Jun 7;12(6):2805-17. doi: 10.1021/pr4001527.
16. Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Res Treat. 2015;154(1):155-62. doi: 10.1007/s10549-015- 3592-z.